Archives: Speakers

Adam has built his career in the commercial workplace industry, working at various scales, and in a range of locations around the world. But most importantly, there is a driving force behind all his designs – creating democratic workplaces that are sustainable for the future. As we spend the majority of our day working, Adam is passionate about delivering places that make people happier, and better able to do their job. Coupled with this, he is keenly aware that as a society we are using too many resources, and he aims to limit his impact on the planet through environmentally responsible design. His care for the environment goes beyond his working life too. As a sustainable and healthy way to travel, he is an advocate of cycling, and believes it will be the future of commuting for most people. For Adam, it is a great way to get in some exercise, drop his kids off at school, and still get into work with time to sp

Aidan is a Board Director and Design Partner at John McAslan + Partners with extensive experience in the design and management of complex urban developments, masterplanning and architecture. He is one of the founding designers of the practice, first joining as a student in the early 1980s. Across the years he has contributed to many of the practice’s most esteemed projects, including the multi-award-winning Roundhouse, King’s Cross Station, and The Olympic Energy Centre in London, and was masterplanner for Lancaster University and The University of Manchester. Internationally, Aidan notably led the transformation of two significant industrial heritage sites in Moscow, the Stanislavsky Factory and the Bolshevik Factory, and also led the practice’s award-winning design of Kericho Cathedral in Kenya. Aidan currently leads the practice’s residential, commercial and urban design studio. Aidan’s signature design skills, drawings and his enthusiasm for finding ‘new ideas for old building,’ is a cornerstone of the practice’s portfolio and long history of adaptive reuse at all scales, as well as its environmental, social and urban philosophy. His work has been reproduced in numerous books, international periodicals and exhibited and awarded at The Royal Academy of Arts, RIBA, The Royal Scottish Academy, L’Arsenal in Paris, The Architecture Foundation and the Institute of Contemporary Art in London and Boston. Aidan is also a visiting critic for several notable institutions including The Strelka Institute in Moscow, The London School of Economics, The Bartlett, Edinburgh School of Art and a fellow of the Royal Society of the Arts and the Royal Incorporation of Scottish Architects.

Andrew is a Founding Director of Waugh Thistleton Architects, a practice dedicated to delivering beautiful buildings and places that acknowledge their effect on the environment. He is a world-renowned spokesperson for low impact architecture and innovative construction, and lobbies and lectures internationally, communicating the urgent need for change to mitigate the climate crisis. A pivotal player in the global shift towards renewable, bio-based materials, Andrew’s innovative approach to design has been acknowledged by many awards including The RIBA President’s Award for Research and a Stirling Prize nomination in 2018. The practice is currently engaged on both research and design projects throughout Europe and North America.

As Head of Hospitality at Areen Design, Andrew is involved in, and monitors all aspects of a project: from initial client contact, brief and concept development through to documentation and site installation. His passion for delivering design solutions which add value, without compromising creative quality, is resolute.

Ellen Weiss joined PCM Trials in April 2019 as Vice President, Business Development. Ms. Weiss has worked to deliver patient-centric services to patients since 2014, including previous roles with CMed Clinical Services and Symphony Clinical Research. Additionally, she has driven the advancement of hospice services at Rainbow Hospice and Palliative Care, a non-profit hospice in Chicago, as both a board member and an on-staff patient advocate. She began her career in the financial services sector and has been an active volunteer for the Healthcare Businesswomen’s Association since 2005, where she works to foster communication across the healthcare industry

Business executive, advisor and entrepreneur Paul’s career includes nearly 20 years of leading companies, product development, global operations, design and adoption of technology in the most difficult of sectors: healthcare and drug development. As Senior Director Paul leads THREAD Consulting in ensuring customers are successful in the strategic design and deployment of technologies throughout the course of their clinical trials.

Claudia Berrón is Avantor’s Senior Vice President, Clinical Services. Claudia has over two decades of experience in B2B strategic marketing covering ideation, value proposition strategies, market segmentation, marketing and sales planning through product launch, and has been working with Avantor since 2015. She holds an MBA from the University of North Carolina Kenan-Flagler Business School in Chapel Hill, North Carolina, and a bachelor’s degree from Monterrey Institute of Technology in Mexico City.

Donald Kellerman is the Vice President of Clinical Development and Medical Affairs for Zosano Pharma. Dr. Kellerman has more than 30 years of experience working in several areas of the pharmaceutical industry, primarily clinical development. Dr. Kellerman has led registration trials in a number of therapeutic areas, including respiratory, allergy, ophthalmology, cardiovascular, and neurology. From 2008 to 2013, Dr. Kellerman served as Senior Vice President, Clinical Development and Medical Affairs at MAP Pharmaceuticals, Inc., where he led the development of Semprana for migraine. Prior to joining MAP, Dr. Kellerman held management positions at Inspire Pharmaceuticals, Inc. Glaxo Wellcome, plc, Sepracor, Inc., Ciba-GEIGY Corporation, and E.R. Squibb and Sons, Inc. He has served as project leader on multiple development teams including those working on Flovent,® Advair,® and Xopenex®. Dr. Kellerman received his Bachelor of Science and Doctor of Pharmacy from the College of Pharmacy at the University of Minnesota. He has authored major sections of eight NDAs, created labelling strategy for several pharmaceutical products, and has co-authored over 80 publications related to the results of clinical development activities.

Dr. Greene is a seasoned pharmaceutical research professional with success both in large pharmaceutical companies and in CROs. He has a PhD and post-doctoral training in psychology and neuroscience, with a focus on the neuroanatomical and neurochemical bases of learning and memory. His career has spanned the full range of clinical development from preclinical pharmacology through late-stage clinical development, successful NDA and MAA submissions, and post approval commitments and label extensions. Dr. Greene has published numerous manuscripts and over thirty abstracts, all focused in CNS research from the bench to clinical work. With over 25 years of experience in the pharmaceutical industry, first as a Lilly Fellow at the Universitè Louis Pasteur in Strasbourg, France, Paul has obtained roles of progressing responsibility at major pharmaceutical companies and CROs. He has experience across a range of CNS disease states with very deep concentrations in mood disorders and schizophrenia. He has worked extensively in pediatric and elderly populations including special institutional environments. At GlaxoSmithKline Dr. Greene led the clinical team through the creation and execution of a clinical development plan for a major marketed product for bipolar disorder. He also led the submission team for a successful NDA and MAA for that product and wrote the Integrated Summary of Efficacy and the Integrated Summary of Benefits and Risks. Having led global project management teams, a rater training enterprise, and large customer relationships at Syneos Health, Dr. Greene brings scientific, operational, and partnership expertise to the relationships in his remit. Paul is Senior Vice President, Global Client Solutions at Syneos Health.

Thomas is a registered nurse with both clinical and over 30 years pharmaceutical development experience. His pharmaceutical development experience includes clinical operations, clinical science, clinical development, drug safety and quality. He is currently Vice President of Clinical Development at Trefoil Therapeutics and adjunct faculty at San Francisco State University.